G1 Therapeutics Inc (GTHX) Shows Strong Revenue Growth and Operational Efficiency in 2023

Photo of author
Written By Kris Enyinnaya

G1 Therapeutics Inc (NASDAQ: GTHX) recently released its financial results for the fourth quarter and full year of 2023, showcasing strong revenue growth driven by sales of its flagship product, COSELA (trilaciclib). 

Strong Revenue Growth and Financial Highlights

In 2023, G1 Therapeutics achieved a remarkable 48% increase in net revenue from COSELA sales, amounting to $46.3 million. The fourth quarter saw a particularly notable 29% growth in net COSELA revenue, reaching $13.9 million. 

Credits: DepositPhotos

Despite challenges such as a platinum-based chemotherapy shortage, COSELA’s sales continued to surge, underscoring its significance in treating extensive-stage small-cell lung cancer. 

Moreover, the company’s financial discipline was evident in reduced operating expenses, with a substantial decrease from $41.1 million in Q4 2022 to $23.8 million in Q4 2023. 

Full-year operating expenses also saw a notable reduction, declining from $187.5 million in 2022 to $122.0 million in 2023. This operational efficiency contributed to a lower net loss of $10.9 million in Q4 2023 compared to $33.6 million in the same quarter of the previous year.

Read More: Zealand Pharma Surges 35% on Promising Weight Loss Drug Results

Research and Development Focus

G1 Therapeutics strategically allocated resources towards key clinical trials, resulting in a significant decrease in research and development expenses. R&D expenses were $7.4 million for Q4 2023, down from $16.6 million in Q4 2022. 

The company’s commitment to advancing its pipeline was evident in ongoing trials, including the Phase 3 PRESERVE 2 trial for metastatic triple-negative breast cancer. 

Preliminary results from a Phase 2 trial also indicated improved overall survival when trilaciclib was used in combination with a TROP2 antibody-drug conjugate, with updated results expected in mid-2024. 

Furthermore, G1 Therapeutics continued to invest in commercialization activities, enhancing its market presence and driving further revenue growth potential.

Outlook for 2024 and Market Prospects

Looking ahead, G1 Therapeutics provided revenue guidance of $60 to $70 million for COSELA in 2024, reflecting confidence in continued sales acceleration in the U.S. market. With a cash position of $82.2 million, the company is well-equipped to fund operations into 2025. 

Moreover, COSELA’s recommendation as a myeloid supportive agent in the updated ASCO SCLC guidelines reinforces its clinical utility and market potential. 

Beyond COSELA, G1 Therapeutics remains committed to advancing its pipeline of novel therapies, leveraging its expertise in cancer treatment to address unmet medical needs and drive long-term value for patients and shareholders alike.

Also Read: Innergex Emerges as Major Renewable Energy Company 

Momentum Points Towards Positive Growth Prospects 

G1 Therapeutics’ robust revenue growth, operational efficiency, and promising clinical developments position the company for sustained success in the biopharmaceutical industry. 

Credits: DepositPhotos

The continued momentum of COSELA sales, coupled with prudent financial management and ongoing clinical trials, bodes well for GTHX’s future growth prospects. 

As the company continues to advance its innovative therapies for cancer treatment, investors can expect G1 Therapeutics to remain a key player in the oncology space, delivering value to patients and shareholders alike.

Read Next: Will PLUG Manage to Recover from Its Tumultuous History? 


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.